On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment ...

SIGA Technologies (SIGA) stock gains as Japan approves antiviral Tepoxx as a treatment for orthopoxviruses including mpox.

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, ...

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distribu ...

Siga Technologies (SIGA)’ antiviral treatment Tepoxx, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as ...

The antiviral drug tecovirimat does not reduce the time to lesion resolution or pain among adults with mild-to-moderate clade ...

Infection with mpox causes a fever and swollen lymph nodes, followed by a distinctive rash that develops into pus-filled blisters. Currently, two companies of Japan and Denmark produce the vaccine ...

North Korea launched an intermediate-range ballistic missile into the East Sea on Monday, South Korea's military said, as U.S ...

SIGA Technologies receives Japanese approval for Tepoxx for the treatment of orthopoxviruses: New York Saturday, January 4, 2025, 12:00 Hrs [IST] SIGA Technologies, a commercial s ...

DAKAR, Dec 12 (Reuters) - Democratic Republic of Congo should start to receive three million doses of mpox vaccine from Japan next week that can be used on children, the Africa Centres for Disease ...

Vaccinations against the potentially deadly infection are under way in Congo, the epicentre of the outbreak, but there have been no shots available for children, who are particularly vulnerable to ...

The Democratic Republic of Congo should start to receive 3 million doses of mpox vaccine from Japan next week that can be used for children, the Africa Centers for Disease Control and Prevention ...